- Home
- NXPL vs QNCX Comparison
NXPL vs QNCX Comparison
Compare NXPL & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | QNCX |
|---|---|---|
| Founded | 1997 | 2012 |
| Country | United States | United States |
| Employees | 130 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 17.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | NXPL | QNCX |
|---|---|---|
| Price | $5.95 | $18.02 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 19.1K | ★ 86.5K |
| Earning Date | 05-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $6.35 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.34 | $0.08 |
| 52 Week High | $8.37 | $20.72 |
Technical Indicators
Market Signals| Indicator | NXPL | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 43.64 | 72.47 |
| Support Level | $5.44 | $16.23 |
| Resistance Level | $7.28 | $19.26 |
| Average True Range (ATR) | 0.56 | 1.35 |
| MACD | -0.11 | -0.43 |
| Stochastic Oscillator | 8.63 | 28.51 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.